Cargando…
Teclistamab: First Approval
Teclistamab (TECVAYLI(®)), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval in the EU for the treatme...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646474/ https://www.ncbi.nlm.nih.gov/pubmed/36352205 http://dx.doi.org/10.1007/s40265-022-01793-1 |